CO5031292A1 - Nuevo tratamiento - Google Patents

Nuevo tratamiento

Info

Publication number
CO5031292A1
CO5031292A1 CO97042582A CO97042582A CO5031292A1 CO 5031292 A1 CO5031292 A1 CO 5031292A1 CO 97042582 A CO97042582 A CO 97042582A CO 97042582 A CO97042582 A CO 97042582A CO 5031292 A1 CO5031292 A1 CO 5031292A1
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
antagonist
composition according
methyl
5ht2c
Prior art date
Application number
CO97042582A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Paul Blackburn
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO5031292A1 publication Critical patent/CO5031292A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO97042582A 1996-07-26 1997-07-25 Nuevo tratamiento CO5031292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment

Publications (1)

Publication Number Publication Date
CO5031292A1 true CO5031292A1 (es) 2001-04-27

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97042582A CO5031292A1 (es) 1996-07-26 1997-07-25 Nuevo tratamiento

Country Status (19)

Country Link
EP (1) EP0936924A2 (hu)
JP (1) JP2000516924A (hu)
KR (1) KR20000029564A (hu)
CN (1) CN1230894A (hu)
AR (1) AR008083A1 (hu)
AU (1) AU725817B2 (hu)
BR (1) BR9710568A (hu)
CA (1) CA2261813A1 (hu)
CO (1) CO5031292A1 (hu)
CZ (1) CZ23799A3 (hu)
GB (1) GB9615767D0 (hu)
HU (1) HUP9903619A3 (hu)
IL (1) IL128219A0 (hu)
NO (1) NO990322L (hu)
NZ (1) NZ333813A (hu)
PL (1) PL331426A1 (hu)
TR (1) TR199900140T2 (hu)
WO (1) WO1998004289A2 (hu)
ZA (1) ZA976593B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
WO2000054764A2 (en) * 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
EP1223939A1 (en) * 1999-05-19 2002-07-24 AstraZeneca AB Method of treating weight gain
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500998D0 (sv) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics

Also Published As

Publication number Publication date
ZA976593B (en) 1999-01-25
HUP9903619A2 (hu) 2000-10-28
HUP9903619A3 (en) 2001-03-28
NO990322L (no) 1999-03-24
PL331426A1 (en) 1999-07-19
WO1998004289A3 (en) 1998-03-19
KR20000029564A (ko) 2000-05-25
EP0936924A2 (en) 1999-08-25
CN1230894A (zh) 1999-10-06
WO1998004289A2 (en) 1998-02-05
CZ23799A3 (cs) 1999-06-16
CA2261813A1 (en) 1998-02-05
IL128219A0 (en) 1999-11-30
NO990322D0 (no) 1999-01-25
BR9710568A (pt) 1999-08-17
NZ333813A (en) 2000-07-28
GB9615767D0 (en) 1996-09-04
AU4297297A (en) 1998-02-20
TR199900140T2 (xx) 1999-03-22
JP2000516924A (ja) 2000-12-19
AU725817B2 (en) 2000-10-19
AR008083A1 (es) 1999-12-09

Similar Documents

Publication Publication Date Title
LU93229I2 (fr) "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
RU97102050A (ru) Гетероциклические антагонисты тахикининовых рецепторов
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
MX9404885A (es) Derivados de ariliden y heteroariliden oxindoles, proceso para supreparacion y composiciones farmaceuticas que los contienen.
EA199800184A1 (ru) Соединение бензимидазола
ES2135707T3 (es) Analogos de la benzamida, utiles como inhibidores de la enzima parp (adp-ribosiltransferasa, adprt) de reparacion del adn.
NO2005019I1 (no) Metylaminolevulina, eventuelt i form av et salt, fortinnsvis metylaminolevulinat-hydroklorid
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
DE59511017D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
CO5031292A1 (es) Nuevo tratamiento
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
NO20025015D0 (no) Et pyridin-1-oksidderivat, og fremgangsmåte for dets overföring til farmasöytisk effektive forbindelser
DE69611728D1 (de) N-(4-substituerte benzyl)-2-aminolactamderivate
CO4410330A1 (es) Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
NO942695D0 (no) Anvendelse av N-(pyridinyl)-1H-indol-1-aminer for fremstilling av et medikament
ES2144888T3 (es) 4-(6-fluoro-(1h)-indol-3-il)-1,2,3,6-tetrahidropiridina sustituida para el tratamiento de desordenes del snc.
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
NO20012538D0 (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
PT804433E (pt) Derivado de indole para o tratamento da enxaqueca
MX9704299A (es) Derivados de bencimidazol.